Biotechnological approach to fight H1N1 influenza

Sep 7 2009

ETBOND TECHNOLOGY defines Biotechnology approach to fight H1N1 Influenza A (Swine Flu)

1. Plan for Morbidity Reduction: H1N1 Influenza A (Swine Flu and its symptoms) is spreading at a lightening speed globally. It is infecting millions of patients since first reported in April, 2009 in Mexico. Costly quarantine and control measures are in place to prevent the spread of the disease from patients to family and contacts in public places.

ETBOND TECHNOLOGY TM Plan: Since the much of spread occur through nasal route, ET 007 SWF is a Biotechnology drug that has been developed to reduce entry and fusion of Influenza A, 2009 (Swine Flu). The drug is assigned a Pre-IND number by FDA.

2. Plan for Mortality Reduction: The current method of medical management of H1N1 Influenza A (Swine Flu) in intensive care unit with the state of the art resources is costly and unmanageable. This is particularly obvious when the looming prospect of 1918 type of anticipated mortality in worst case scenario is considered.

ETBOND TECHNOLOGY^TM Plan: Since much of the mortality is related to adverse interactions of virus with immune system that cause lung infection and death. ET 007 SWF is a biotechnology product advanced to Pre-IND stage with FDA. The drug will reduce the cost and management of H1N1 influenza A (Swine Flu) by providing antiviral and anti-inflammatory defenses in a safe way.

3. Plan for Vaccine Fears: Currently there is growing fear that preventive vaccine may not induce timely immune responses and it may be associated with severe adverse effects as seen in past.

ETBOND TECHNOLOGY TM Plan: The Company has advanced a biotechnology product to stimulate immune system while targeting virulence pathway with ET 007 SWF. This will shorten the duration needed for immune responses and will reduce adverse effects in the immediate post-vaccination time. FDA has assigned Pre-IND Number.

4. Plan for Global Consultancy: This is offered for H1N1 Influenza A (Swine Flu) through our web-site that provides online medical consultancy services to all players in life sciences after fee based registration.